Company Press Release - Success of Human Genome Project Further Substantiates the Need for GeneLink
Tuesday March 23, 7:32 am

MARGATE, N.J.--(BW HealthWire)--March 23, 1999--GeneLink Inc. (OTC BB:GNLK-news) Representatives from The Human Genome Project - a global undertaking set to map and sequence all human genes - recently announced they will release the first draft (90% of the 3 billion DNA sequences) next February, one year ahead of schedule.

Such mapping of the entire genome, the genetic map that defines the human species, promises to revolutionize medicine and provide new treatment for numerous diseases. 

"As research continues to produce new findings in diseases such as cancer, diabetes and Alzheimers's, early detection and treatment will change the way we view medicine," states John R. DePhillipo, GeneLink's Chairman and CEO. ''With the imminent completion of The Human Genome Project, the public is starting to understand how DNA storage will allow future generations to take full advantage of such findings." 

The Margate based company produces a DNA Collection Kit (on which patents are pending)-a safe, easy, non-invasive method of extracting one's DNA and storing it at the University of North Texas Health Science Center in Fort Worth, Texas. GeneLink provides the opportunity for families to bank their DNA for generations, providing a genetic family history that can be used to aid in healthcare treatment. 

More importantly, banked DNA becomes a major catalyst in shifting the practice of medicine from diagnosis and treatment to prediction and prevention. 

"The more genes we become aware of, the more people will realize the important of storing their genetic makeup. This reinforces the need for a product that offers confidential, guaranteed DNA banking. We anticipate a surge in inquiries and sales as a result,'' says DePhillipo. 

Forward-Looking Statements: This news release contains certain "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a new "safe harbor'' for these types of statements. 

To the extent statements in this news release involve, without limitation, product development and introduction plans, the Company's expectations for growth, estimates of future revenue, expenses, profit, cash flow, balance sheet items, sell-through or backlog, forecasts of demand or market trends for the Company's product categories and for the industries in which the Company operates, or any other guidance on future periods, these statements are forward-looking statements. 

The Company assumes no obligation to update forward-looking statements. 

SOURCE: GeneLink BioSciences, Inc.